{
    "clinical_study": {
        "@rank": "1633", 
        "arm_group": {
            "arm_group_label": "Patients on Avastin maintenance treatment"
        }, 
        "brief_summary": {
            "textblock": "This is a prospective, open-label, single arm, non-interventional study will investigate the\n      effectiveness of Avastin monotherapy for patients with lung adenocarcinoma who previously\n      received 4 to 6 cycles of induction platinum doublet plus Avastin. The study is expected to\n      last approximately 34 months."
        }, 
        "brief_title": "A Study Examining Maintenance Avastin Monotherapy in Patients With Advanced Lung Adenocarcinoma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Lung Adenocarcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years or older\n\n          -  Patients who previously received 4 to 6 cycles of induction platinum doublet plus\n             bevacizumab\n\n          -  Patients who received only 1 cycle of bevacizumab maintenance treatment\n\n          -  meet summary of product characteristics guidelines\n\n        Exclusion Criteria:\n\n          -  Patients who received the first cycle of maintenance bevacizumab more than 4 weeks\n             after the postinduction tumor assessment\n\n          -  Pregnant or breast-feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients receiving Avastin monotherapy as maintenance treatment"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093000", 
            "org_study_id": "ML29261"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 26, 2014", 
        "number_of_groups": "1", 
        "official_title": "A Multicenter, Prospective, Non-interventional Study of Maintenance Avastin (Bevacizumab) Following Induction Treatment With Platinum Doublet Plus Avastin in Patients With Advanced Lung Adenocarcinoma", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML29261 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "HUNGARY: Gyogyszereszeti \u00e9s Egeszsegugyi Minoseg- es Szervezetfejlesztesi Intezet Orszagos Gyogyszereszeti Intezet"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival (PFS), defined as time from first dose of maintenance Avastin treatment until disease progression or death from any cause.", 
            "safety_issue": "No", 
            "time_frame": "Up to 34 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093000"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "PFS, defined as time from first dose of induction Avastin treatment until disease progression or death from any cause.", 
                "safety_issue": "No", 
                "time_frame": "Up to 34 months"
            }, 
            {
                "measure": "1 year overall survival defined as time from first dose of induction Avastin treatment until death from any cause.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Best overall response", 
                "safety_issue": "No", 
                "time_frame": "Up to 34 months"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Up to 34 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}